The SurVaxM peptide vaccine conjugate, designed to target survivin, a molecule highly expressed in GBM cells, has shown significant efficacy when administered to patients newly diagnosed with GBM in combination with temozolomide.48 Here, BIRC5 is linked to glioblastoma.